Recently, pharmaceutical companies have been keen to participate in funds and invest in biomedicine and other fields

【Pharmaceutical Network Industry News】On November 10, Youningwei announced that the company intends to participate in the Shanghai Leading Relay Private Equity Partnership (Limited Partnership) for 50 million yuan, which will mainly focus on digital economy, advanced manufacturing, medical and health, consumer services and other industries to carry out investment
.
The paid-up capital contribution of the fund shall be directly or indirectly invested in the private equity investment funds
of enterprises in the above industries.
Also on the evening of the 10th, Tailong Pharmaceutical disclosed an announcement that its wholly-owned subsidiary Tailong Health Industry Investment Co.
, Ltd.
plans to invest 220 million yuan with the company's indirect controlling shareholders to establish Longhua Pharmaceutical Industry Fund
with a total scale of 400 million yuan.
The fund will focus on the company's development strategy and focus on investing in early-stage and growth-stage healthcare projects with rapid growth potential, including but not limited to projects in traditional Chinese medicine, innovative drugs and biotechnology, medical devices and diagnostic technologies, pharmaceutical R&D services and digital health
, as well as consumer health.
On November 3, Sunnovo announced that the company intends to subscribe for the capital contribution of Zhongda Pharmaceutical Fund with its own funds of RMB 30 million, accounting for 6.
00%
of the total subscribed capital contribution of Zhongda Pharmaceutical Fund.
The fund focuses on investing in emerging industries such as life and health, new drug creation, and precision medicine, promotes the sharing and integration of advantageous resources, deepens cooperation between all parties, and realizes the integration
of industry and capital.
On November 2, OPCOM announced that OPPLE Investment, a wholly-owned subsidiary of the company, intends to invest RMB 115 million with its own funds to participate in the establishment of the fund Anhui Shanhong Venture Capital Partnership (Limited Partnership).

The fund mainly invests in innovative medical devices, biomedicine and medical service companies, focusing on medical device segments, focusing on investment projects in ophthalmology and optometry, interventional devices and consumables, new biological materials, IVD fields, minimally invasive surgery and surgical robots
.
.
.
.
.
.
.
It can be seen that pharmaceutical companies have recently been keen to participate in funds and invest in fields
including biomedicine.
In terms of subdivisions, it mainly includes traditional Chinese medicine, innovative drugs, innovative medical devices, pharmaceutical R&D services, digital medicine, consumer health and other fields, these tracks are relatively prosperous, supported by policies are relatively large, and have broad
prospects.
Most pharmaceutical companies participate in the establishment of industrial funds to accelerate the company's business expansion
.
As OPCOM said in the announcement, the fund will invest in new technologies and products consistent with the company's development plan, including ophthalmic and optometry products, as well as other life and health products
with market potential.
Investment in new technologies and new product research and development enterprises is one of the three channels for the company's independent research and development, commissioned research and development and investment in new products, and is an integral part of
the company's R & D investment.
CRO company Sunnovo also said that its investment fund investment field has a synergistic relationship
with the company's current main business.
In addition, investing in the fund will also help to improve the efficiency of capital use and obtain certain investment income with the help of the investment ability of professional investment institutions, and this investment will not affect the normal development
of the company's main business.
Tailong Pharmaceutical will take advantage of the capital advantages of indirect controlling shareholders and the resource advantages of its subordinate state-owned professional investment institutions to accelerate the company's industrial layout in the fields of biomedicine and general health, and form synergy with the company's existing business, which is conducive to improving the company's capital operation ability, industrial layout ability and sustainable profitability
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.